ID

13806

Descrição

Monitoring Minimal Residual Disease Following Treatment of Patients With Acute Myeloid Leukemia (AML) or High Grade Myelodysplastic Syndrome (MDS); ODM derived from: https://clinicaltrials.gov/show/NCT01311258

Link

https://clinicaltrials.gov/show/NCT01311258

Palavras-chave

  1. 07/03/2016 07/03/2016 -
Titular dos direitos

CC BY-NC 3.0

Transferido a

7 de março de 2016

DOI

Para um pedido faça login.

Licença

Creative Commons BY-NC 3.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Acute Myeloid Leukemia NCT01311258

Eligibility Acute Myeloid Leukemia NCT01311258

Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
are being evaluated for the diagnosis and/or treatment of acute myelogenous leukemia or high grade mds (defined as greater than 10 percent blasts on examination of the bone marrow aspirate).
Descrição

AML MDS

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0023467
UMLS CUI [2]
C3463824
have not undergone prior cytotoxic therapy for aml or high grade mds in the past 3 months other than hydroxyurea or revlamid.
Descrição

prior therapy

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0677881
UMLS CUI [2]
C0591617
have not previously received an allogeneic peripheral blood or bone marrow stem cell transplant for their disease.
Descrição

allogeneic peripheral blood or bone marrow stem cell transplant

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1518999
UMLS CUI [2]
C0842093
are able to sign an informed consent. informed consent must be signed at the time of enrollment and prior to the collection of any specimens and/or clinical data (other than phi needed to screen and identify patients, which will be promptly discarded in a secure fashion if patient is not enrolled on study)
Descrição

informed consent

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0021430
are at least 18 years of age.
Descrição

age

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001779
do not have any serious medical or psychiatric illness, other than that treated by this study which would limit the ability of the patient to receive therapy or give informed consent.
Descrição

comorbidity

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0009488
have been informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines.
Descrição

informed consent

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects who are less than 18 years of age.
Descrição

age

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001779
subjects with limited decision making capacity.
Descrição

subjects with limited decision making capacity.

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
subjects who have received prior cytotoxic therapy, other than hydroxyurea or revlamid, for their disease within the past three months.
Descrição

prior cytotoxic therapy

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0677881
UMLS CUI [2]
C0591617
patients with a diagnosis of cml in blast crisis, acute promyelocytic leukemia, or bi-lineage leukemia.
Descrição

cml in blast crisis, apl

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0023473
UMLS CUI [1,2]
C0005699
UMLS CUI [2]
C0023487
UMLS CUI [3]
C4023020
subjects who have previously undergone an allogeneic peripheral blood stem cell transplant.
Descrição

allogenic blood stem cell transplant

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0242602
UMLS CUI [1,2]
C1515895
have an active malignancy other than aml or mds at the time of evaluation or a prior history of treatment for a malignancy other than aml or mds within the past 2 years.
Descrição

other malignancy

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0205394
UMLS CUI [2,1]
C1514463
UMLS CUI [2,2]
C0003392

Similar models

Eligibility Acute Myeloid Leukemia NCT01311258

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
AML MDS
Item
are being evaluated for the diagnosis and/or treatment of acute myelogenous leukemia or high grade mds (defined as greater than 10 percent blasts on examination of the bone marrow aspirate).
boolean
C0023467 (UMLS CUI [1])
C3463824 (UMLS CUI [2])
prior therapy
Item
have not undergone prior cytotoxic therapy for aml or high grade mds in the past 3 months other than hydroxyurea or revlamid.
boolean
C1514463 (UMLS CUI [1,1])
C0677881 (UMLS CUI [1,2])
C0591617 (UMLS CUI [2])
allogeneic peripheral blood or bone marrow stem cell transplant
Item
have not previously received an allogeneic peripheral blood or bone marrow stem cell transplant for their disease.
boolean
C1518999 (UMLS CUI [1])
C0842093 (UMLS CUI [2])
informed consent
Item
are able to sign an informed consent. informed consent must be signed at the time of enrollment and prior to the collection of any specimens and/or clinical data (other than phi needed to screen and identify patients, which will be promptly discarded in a secure fashion if patient is not enrolled on study)
boolean
C0021430 (UMLS CUI [1])
age
Item
are at least 18 years of age.
boolean
C0001779 (UMLS CUI [1])
comorbidity
Item
do not have any serious medical or psychiatric illness, other than that treated by this study which would limit the ability of the patient to receive therapy or give informed consent.
boolean
C0009488 (UMLS CUI [1])
informed consent
Item
have been informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
age
Item
subjects who are less than 18 years of age.
boolean
C0001779 (UMLS CUI [1])
subjects with limited decision making capacity.
Item
subjects with limited decision making capacity.
boolean
C0021430 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
prior cytotoxic therapy
Item
subjects who have received prior cytotoxic therapy, other than hydroxyurea or revlamid, for their disease within the past three months.
boolean
C1514463 (UMLS CUI [1,1])
C0677881 (UMLS CUI [1,2])
C0591617 (UMLS CUI [2])
cml in blast crisis, apl
Item
patients with a diagnosis of cml in blast crisis, acute promyelocytic leukemia, or bi-lineage leukemia.
boolean
C0023473 (UMLS CUI [1,1])
C0005699 (UMLS CUI [1,2])
C0023487 (UMLS CUI [2])
C4023020 (UMLS CUI [3])
allogenic blood stem cell transplant
Item
subjects who have previously undergone an allogeneic peripheral blood stem cell transplant.
boolean
C0242602 (UMLS CUI [1,1])
C1515895 (UMLS CUI [1,2])
other malignancy
Item
have an active malignancy other than aml or mds at the time of evaluation or a prior history of treatment for a malignancy other than aml or mds within the past 2 years.
boolean
C0006826 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C1514463 (UMLS CUI [2,1])
C0003392 (UMLS CUI [2,2])

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial